Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations.

[1]  Unión,et al.  Bortezomib/Cyclophosphamide/Dexamethasone Regimen , 2020, Definitions.

[2]  P. Selvaraj,et al.  Formulation and evaluation of a particulate oral breast cancer vaccine. , 2012, Journal of pharmaceutical sciences.

[3]  Xianghui Yu,et al.  DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model , 2012, Cancer Immunology, Immunotherapy.

[4]  H. Lyerly,et al.  Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. , 2012, Seminars in oncology.

[5]  J. Schlom,et al.  Therapeutic cancer vaccines: current status and moving forward. , 2012, Journal of the National Cancer Institute.

[6]  C. Morrison,et al.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients , 2012, Proceedings of the National Academy of Sciences.

[7]  P. Selvaraj,et al.  Oral microparticulate vaccine for melanoma using M-cell targeting , 2012, Journal of drug targeting.

[8]  S. Geary,et al.  Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines. , 2011, Molecular pharmaceutics.

[9]  S. Geary,et al.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN , 2011, Cancer Immunology, Immunotherapy.

[10]  A. Hemminki,et al.  Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients , 2011, The journal of gene medicine.

[11]  G. Vassaux,et al.  Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. , 2011, Vaccine.

[12]  M. Krupa,et al.  Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. , 2011, Vaccine.

[13]  Chandan Thomas,et al.  Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. , 2011, Molecular pharmaceutics.

[14]  M. Ozkan,et al.  Delivery of a peptide via poly(D,L-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[15]  K. Legge,et al.  Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly , 2010, Proceedings of the National Academy of Sciences.

[16]  T. Ratliff,et al.  Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results , 2009, Clinical Cancer Research.

[17]  H. Pircher,et al.  Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T‐cell‐independent CD8+ T‐cell‐mediated tumor control , 2009, European journal of immunology.

[18]  J. Schlom,et al.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. , 2009, Vaccine.

[19]  A. Salem,et al.  Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma , 2009, Cancer Immunology, Immunotherapy.

[20]  D. Karan,et al.  CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. , 2009, Advanced drug delivery reviews.

[21]  A. Salem,et al.  Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[22]  D. Karan,et al.  Paradoxical enhancement of CD8 T cell‐dependent anti‐tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine , 2007, International journal of cancer.

[23]  A. Salem,et al.  Potent Antigen-specific Immune Responses Stimulated by Codelivery of CpG ODN and Antigens in Degradable Microparticles , 2007, Journal of immunotherapy.

[24]  M. Barry,et al.  Current advances and future challenges in Adenoviral vector biology and targeting. , 2007, Current gene therapy.

[25]  Michael P. Andrews,et al.  Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. , 2006, Vaccine.

[26]  D. Hart,et al.  Generation of tumor-specific T-cell therapies. , 2006, Blood reviews.

[27]  Daniel G. Anderson,et al.  pH-Triggered Microparticles for Peptide Vaccination1 , 2004, The Journal of Immunology.

[28]  M. Roth,et al.  Modifying adenoviral vectors for use as gene-based cancer vaccines. , 2004, Viral immunology.

[29]  H. Merkle,et al.  Composition and Surface Charge of DNA-Loaded Microparticles Determine Maturation and Cytokine Secretion in Human Dendritic Cells , 2004, Pharmaceutical Research.

[30]  David L Woodland,et al.  Jump-starting the immune system: prime-boosting comes of age. , 2004, Trends in immunology.

[31]  J. Schlom,et al.  Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. , 2003, Cancer research.

[32]  B. Gander,et al.  Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. , 2003, Vaccine.

[33]  John Samuel,et al.  Analysis of Poly(D,L-Lactic-Co-Glycolic Acid) Nanosphere Uptake by Human Dendritic Cells and Macrophages In Vitro , 2002, Pharmaceutical Research.

[34]  B. Gander,et al.  In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  T. Ratliff,et al.  Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (alvac) cytokine gene delivery induces destruction of established prostate tumors , 2001, International journal of cancer.

[36]  H. Merkle,et al.  Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[37]  D. Siemens,et al.  Cutting Edge: Restoration of the Ability to Generate CTL in Mice Immune to Adenovirus by Delivery of Virus in a Collagen-Based Matrix , 2001, The Journal of Immunology.

[38]  A. Ramsay,et al.  The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.

[39]  M. Plebanski,et al.  Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies , 1999, Immunological reviews.

[40]  G. Schuler,et al.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. , 1999, Journal of immunological methods.

[41]  J. Harty,et al.  Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. , 2011, Advances in experimental medicine and biology.

[42]  A. Salem,et al.  Development of an MHC class I L d -restricted , 2010 .

[43]  B. Gander,et al.  Delivery of tumor antigens to dendritic cells using biodegradable microspheres. , 2005, Methods in molecular medicine.

[44]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.